LivaNova (NASDAQ:LIVN) Upgraded by Freedom Capital to “Hold” Rating

Freedom Capital upgraded shares of LivaNova (NASDAQ:LIVN) to a hold rating in a report issued on Tuesday morning,Zacks.com reports.

A number of other research firms also recently commented on LIVN. Mizuho lifted their price objective on shares of LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Weiss Ratings raised shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Robert W. Baird reduced their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. KeyCorp lifted their price target on shares of LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Monday, June 22nd. Finally, Barclays boosted their price objective on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $80.75.

LivaNova Trading Up 1.4%

Shares of NASDAQ LIVN opened at $83.62 on Tuesday. The stock’s 50 day moving average price is $73.58 and its two-hundred day moving average price is $67.51. LivaNova has a 52-week low of $41.01 and a 52-week high of $83.98. The stock has a market capitalization of $4.59 billion, a P/E ratio of 42.88 and a beta of 0.86. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The company had revenue of $362.26 million during the quarter, compared to analyst estimates of $346.05 million. During the same quarter last year, the firm earned $0.88 EPS. The business’s revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, analysts anticipate that LivaNova will post 3.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the sale, the director directly owned 7,228 shares of the company’s stock, valued at $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.35% of the stock is currently owned by insiders.

Institutional Investors Weigh In On LivaNova

Hedge funds have recently added to or reduced their stakes in the stock. Hantz Financial Services Inc. increased its holdings in shares of LivaNova by 159.9% in the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after acquiring an additional 267 shares during the period. State of Wyoming acquired a new position in LivaNova during the 2nd quarter valued at about $31,000. EverSource Wealth Advisors LLC boosted its stake in LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after purchasing an additional 639 shares during the period. Quarry LP bought a new position in LivaNova in the 3rd quarter worth about $36,000. Finally, Covestor Ltd grew its position in LivaNova by 108.6% in the 4th quarter. Covestor Ltd now owns 753 shares of the company’s stock worth $46,000 after purchasing an additional 392 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.